3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Carcinoma
2
Breast Neoplasms
2
Vomiting
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Postoperative Nausea and Vomiting
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Liposarcoma
1
Leukemia, Hairy Cell
1
Histiocytoma, Malignant Fibrous
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Carcinoma In Situ
1
Adenocarcinoma, Mucinous
1
Interventions
Doxorubicin
3
pembrolizumab
2
pazopanib
2
Radiotherapy
2
Radiation
2
Ifosfamide
2
selinexor
1
peposertib
1
liposomal doxorubicin
1
avelumab
1
Specimen Handling
1
Quality of Life
1
Proton Therapy
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Immune Checkpoint Inhibitors
1
Imatinib Mesylate
1
Histamine H2 Antagonists
1
Famotidine
1
Dactinomycin
1
Cyclophosphamide
1
Blood Specimen Collection
1
Biopsy
1
BO-112
1
Angptl4 protein, mouse
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Dermatofibrosarcoma
×
Famotidine
×
1 year
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled